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As a single receptor, the neonatal Fc receptor (FcRn) is critically involved in regulating albu-
min and IgG serum concentrations by protecting these two ligands from degradation. In
addition to these essential homeostatic functions, FcRn possesses important functions
in regulating immune responses that are equally as critical and are increasingly coming
to attention. During the first stages of life, FcRn mediates the passive transfer of IgG
across the maternal placenta or neonatal intestinal walls of mammals, thereby conferring
passive immunity to the offspring before and after birth. In fact, FcRn is one of the very
few molecules that are known to move from luminal to serosal membranes of polarized
cells that form epithelial barriers of the lung and intestines. Together with FcRn’s recently
explored critical role in eliciting MHC II presentation and MHC class I cross-presentation of
IgG-complexed antigen, this renders FcRn capable of exerting broad and potent functions
in regulating immune responses and immunosurveillance at mucosal sites. Further, it is
now clear that FcRn dependent mucosal absorption of therapeutic molecules is a clinically
feasible and potent novel route of non-invasive drug delivery, and the interaction between
FcRn and IgG has also been utilized for the acquisition of humoral immunity at mucosal
sites. In this review, we begin by briefly summarizing the basic knowledge on FcRn expres-
sion and IgG binding, then describe more recent discoveries pertaining to the mechanisms
by which FcRn orchestrates IgG related mucosal immune responses and immunosurveil-
lance at host–environment interfaces within the adult organism. Finally, we outline how
the knowledge of actions of FcRn at mucosal boundaries can be capitalized for the devel-
opment and engineering of powerful mucosal vaccination strategies and novel routes for
the non-invasive delivery of Fc-based therapeutics.
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FcRn BINDS IgG MOLECULES THROUGHOUT ADULT LIFE
FcRn, encoded by the Fcgrt gene, is an MHC class I-like trans-
membrane protein that requires non-covalent association with
β2-microglobulin (β2-m) for proper functioning. In its best
known function, FcRn binds to the CH2-CH3 interface of the
IgG Fc region in a 2:1 stoichiometry (1–3). Binding between
IgG and FcRn occurs in a strictly pH-dependent manner with
micro- to nanomolar affinity at pH 6.5 while binding is virtually
absent at pH 7.5 (4, 5). As revealed by site-directed mutagene-
sis, the residues Ile253, His310, and His435 of IgG are critically
involved in its interaction with FcRn (4, 6–8). Consistent with
such strict pH-dependent binding, the bulk of FcRn is expressed
intracellularly – predominantly in endosomes – and such that
the interaction between FcRn and its ligands occurs within an
intracellular acidic milieu (9–12). Although originally viewed as
a receptor restricted to neo- and antenatal life, it is now clear
that FcRn continues to function throughout adult life and is
expressed lifelong in both parenchymal cells (epithelium of the
lung and intestine as well as the liver and vascular endothelium)
and hematopoietic cells [monocytes, macrophages, dendritic cells
(DCs), polymorphonuclear leukocytes, and B cells] in mouse and
humans [as reviewed elsewhere (13–17)]. Apart from regulating
and extending the serum half-life of IgG by a mechanism that
is operative in DCs and endothelial cells (18–21), FcRn orches-
trates IgG-based immune responses at mucosal sites. Collectively,
the numerous functions of FcRn enable it to act as a sensitive
regulator of mucosal immunity via bidirectional transcytosis of
IgG and luminal antigens across epithelial boundaries as well as
the active induction of MHC II presentation and MHC I cross-
presentation pathways for the generation of antigen-specific T-cell
responses.
MUCOSAL IMMUNE REGULATION AND
IMMUNOSURVEILLANCE BY FcRn
Apart from being responsible for the transplacental transfer of
maternal IgG to a human fetus, FcRn has been shown to mediate
the bidirectional transport of IgG across all polarized epithelial
barriers including those of the gastrointestinal and respiratory
tract, the placenta, and the genitourinary system including kidneys
(8, 22–29). Further, it has been documented that this mecha-
nism is operative not only in humans and mice but also in rats,
pigs, and non-human primates, implying that the transepithelial
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IgG transport across mucosal membranes is an evolutionarily
well conserved and thus important part of immune regulation.
By expressing FcRn, the epithelial barrier thus gains the abil-
ity to transport IgG from the basolateral to the apical side and
vice versa, or, in other words, to deliver IgG into the lumen from
the tissue space and, subsequently, transport IgG-bound lumi-
nal antigens back to the lamina propria (LP). This process is of
utmost importance for immune regulation at mucosal barriers
and in vivo studies have impressively demonstrated that FcRn
is indeed a key molecule in integrating humoral and cellular
immunity and intraluminal (and thereby foreign) signals into
the host intramural immune system. To mirror the situation in
humans, these studies utilized humanized mice in which a human
FcRn transgene (together with human β2-m) was expressed in
a mouse that was devoid of mouse FcRn (30, 31). In vivo stud-
ies using the model antigen ovalbumin (OVA) demonstrated that
after intravenous injection of anti-OVA IgG and subsequent oral
feeding of fluorescently labeled OVA, OVA-IgG immune com-
plexes (ICs) formed within the gastrointestinal lumen and were
transported in an FcRn dependent manner into the LP where the
antigen–antibody complex was taken up by CD11c+ DCs which,
upon MHC II presentation of OVA epitopes, were then able to
induce an antigen-specific CD4+ T-cell response (31). Of note,
the mechanism of FcRn-mediated transfer of antigen-specific IgG
and subsequent induction of an antigen-specific T-cell response
was not limited to the intestinal tract, as nasal administration
of OVA after intravenous injection of anti-OVA IgG led to a
similar FcRn-mediated uptake of antigen–antibody ICs and an
expansion of antigen-specific CD4+ T-cells in the nasal-associated
lymphatic tissue (31). This mechanism has direct physiologic and
immunopathogenic relevance: when challenged with Citrobacter
rodentium – which models enteropathogenic Escherichia coli infec-
tion – mice with restricted expression of FcRn solely within the
intestinal epithelium, but not FcRn deficient animals, were pro-
tected from infection but only in the presence of anti-C. rodentium
IgG antibodies, consistent with IgG being a main effector mole-
cule in the eradication of this pathogen (32–34). To mount an
effective immune response against this epithelial pathogen, FcRn
was shown to mediate the following processes (Figure 1): (I.)
transport of pathogen-specific IgG from the systemic circulation
across the epithelial barrier into the intestinal lumen, (II.) uptake
of the newly formed ICs consisting of bacteria and anti-bacterial
IgG and transcytosis of these into the LP, and (III.) induction
of an antigen-specific immune response and T-cell expansion
within regional lymphoid structures and associated peripheral
tissues (34).
FIGURE 1 | FcRn-mediated functions in immune surveillance and
homeostasis at the intestinal epithelial barrier (16, 31, 34). FcRn within
enterocytes can transport IgG from the systemic circulation across the
epithelial barrier into the intestinal lumen (I.). Upon formation of immune
complexes (ICs) consisting of bacteria and anti-bacterial IgG within the
intestinal lumen, FcRn can transcytose these back into the LP (II.). In the LP,
the ICs are delivered to antigen-presenting cells (APCs) from which the ICs
are taken up via canonical FcγR’s. Once internalized into the cell, the ICs are
then directed into acidic endosomes, in which FcRn is operative to mediate
the presentation of IC derived antigen to antigen-specific T-cells (III.).
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Thus, these studies provide direct evidence that epithelial
expression of FcRn is able to link luminal and/or epithelial infec-
tious exposures with systemic immune activation. FcRn expres-
sion in the gastric epithelium and the associated transport of
pathogen-specific IgG across the gastric epithelium is also linked
to the prevention of gastric colonization and invasion by the
pathogens Helicobacter heilmannii and Helicobacter pylori (35).
Similarly, FcRn within the genitourinary and respiratory tract
enables the transmucosal transport of pathogen-specific IgG and
has been associated with the prevention of viral infection, as
shown in model studies mirroring herpes simplex 2 or influenza
infection (24, 29).
FcRn’S ROLE IN ANTIGEN PRESENTATION BY
PROFESSIONAL ANTIGEN-PRESENTING CELLS AT MUCOSAL
SURFACES
CLASSICAL MHC II PRESENTATION OF IMMUNE COMPLEXED ANTIGEN
While the later studies mainly investigated FcRn’s function of pro-
viding passive immunity by transcytosing IgG across the mucosal
barrier, the discoveries that FcRn within the DC is deeply involved
in the generation of antigen-specific T-cell responses opened up
another dimension in FcRn’s pleiotropic functions for immune
homeostasis. One critical prerequisite for addressing FcRn’s role
in antigen presentation is to carefully control IgG levels. Both
hematopoietic cells and parenchymal cells are equally responsi-
ble for protecting IgG from degradation (18–21, 30), and in order
to account for IgG deficiency in Fcgrt−/− mice, the utilization of
bone-marrow chimeric mice is an elegant approach to circum-
vent differences in IgG levels between WT and Fcgrt−/− mice, as
previously shown (18, 19, 21).
After having shown that FcRn is expressed in professional APC
in human and mouse (18, 19, 21, 31, 36–38), it was demon-
strated that FcRn in DCs enhances MHC II antigen presentation
and induces proliferation of antigen-specific CD4+ T-cells when
antigen is presented as a multimeric IC with IgG, both in vitro
and in vivo (21), and this observation was also confirmed in
humans (39). Furthermore, both murine and human studies have
demonstrated that ICs containing a non-FcRn-binding IHH-IgG
mutant, which harbors three mutations that disable binding to
FcRn (I253A, H435A, and H436A) (7), do not lead to T-cell
activation (21). Importantly, the studies showed that this regu-
lation is only observed when the IgG–antigen complex is provided
as a multimeric IC, suggesting that FcRn directs the intracellu-
lar trafficking of its ligands differently depending on the valency
of the bound ligands. This concept was supported by confocal
microscopy showing that multimeric IgG ICs, but not IHH-IgG1
ICs or monomeric ICs, were rapidly internalized by human DCs
and co-localized with FcRn first in membrane-proximal intra-
cellular compartments, presumably early endosomes, and subse-
quently in LAMP1-positive lysosomes, thus indicating that FcRn
directs multimeric ICs into a cellular compartment equipped with
the machinery to induce MHC II antigen presentation (39). Using
bone-marrow chimeric mice, it was then directly shown that the
fate and also the associated serum half-life are indeed funda-
mentally different depending on the ligand valency. IgG present
in multimeric ICs exhibited rapidly increased degradation medi-
ated by hematopoietic cells, presumably DCs, consistent with an
in vivo fate of active trafficking toward lysosomal degradation
rather than FcRn-mediated recycling. However, unbound IgG or
IgG in monomeric complexes were protected from degradation in
an FcRn dependent manner from both hematopoietic and myeloid
cells (39). Thus, these studies show that FcRn determines the fate
of IgG depending on the nature of the ligand. In a more general
sense, these findings illustrate that FcRn actively senses whether an
antigen has already been IgG opsonized, in which case the IC are
routed towards antigen presentation compartments, or whether
IgG is unbound and thus should be protected from degradation.
MHC I CROSS-PRESENTATION OF IMMUNE COMPLEXED ANTIGEN
Recent studies further extend the understanding of the critical
involvement of FcRn in antigen presentation at mucosal surfaces.
Strikingly, CD8−CD11b+ DCs loaded with IgG-complexed OVA
induced robust proliferation of adoptively transferred OT-I T-cells
in an entirely FcRn-dependent manner (36). These studies were
the first to discover that FcRn exhibits also a fundamental role in
the presentation of exogenous antigen to CD8+ T-cells, a process
called cross-presentation (36, 40). These studies also demonstrated
that FcRn within CD8−CD11b+ DCs directed the IgG ICs into a
Rab27a, vacuolar ATPase, and gp91phox containing acidic phago-
some that allowed for cross-presentation (36). Further, utilizing
antibodies that have no affinity for FcRn, but intact affinity for
canonical FcγRs (IHH-IgG) or which cannot bind FcγRs, but
retain the ability to bind FcRn [N297A-IgG (41)], it was shown
that canonical FcγRs on the surface of DCs mediate the entry of
the ICs into the cell which then are further directed and trafficked
in an FcRn dependent fashion as outlined above (36). Thus, FcRn
and canonical surface FcγR’s cooperate in inducing antigen pre-
sentation and the pH-dependent ligand binding of FcRn and its
expression within the acidic milieu of endosomal compartments
is perfectly suited to further handle, traffic and process IgG and
ICs once bound at neutral pH by FcγRs and internalized.
The mechanisms and pathophysiological significance of FcRn
dependent cross-presentation to DCs at mucosal surfaces has
recently been analyzed (37). First, these studies demonstrated that
untreated Fcgrt−/− mice exhibit decreased numbers of CD8+
T-cells within the LP of the large intestine, and that these
were also deficient in cytokine production. The utilization of
CD11cCreFcgrtFl/Fl mice (37) has shown that FcRn expression in
DCs is critical for this. Second, FcRn within DCs was not only
shown to be required for homeostatic CD8+ T-cell activation but
also conferred protection from cancer development at mucosal
sites, namely, the large intestine and the lung. This was reliant
on the FcRn dependent induction of endogenous CD8+ T-cells
towards cognate tumor antigens, and thus, these studies were the
first to identify a deep involvement of FcRn in the protection
from cancers arising at mucosal tissues. As an additional mech-
anism behind these observations, cross-linking of FcRn by IgG IC
induced secretion of the cytotoxicity-promoting cytokine IL-12,
thereby providing an additional stimulus to activate antigeni-
cally primed specific CD8+ T-cells (37). Importantly, analysis of
the overall microbial community composition and diversity from
wildtype and Fcgrt−/− littermates revealed no significant differ-
ences in either post-weaning, 8-week-old mice or pre-weaning,
2-week-old mice in any of three separate intestine-associated tissue
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compartments, thereby confirming that the induction of mucosal
CD8+ T-cells in FcRn bearing mice was not due to changes in the
intestinal microbiota (37).
These findings are directly translatable to human pathology
such that human DCs expressing high levels of FcRn co-localize
with CD8+ T-cells in the stroma of both normal and colorectal
cancer (CRC) large intestine and induce IL-12 production in an
FcRn-dependent manner. Further, survival analysis indicated that
CRC patients with≥10 FcRn+CD11c+ cells per observed area had
significantly longer survival times over a 70-month follow up than
did those with <10 FcRn+CD11c+ cells in the tumor microenvi-
ronment (37). Finally, this mechanism was shown to be amenable
to therapeutic manipulation. When ICs were formed with an engi-
neered IgG variant known to exhibit enhanced FcRn binding with
maintained pH dependency (42), antigen-specific CD8+ T-cell
activation was induced at antigen concentrations 10-fold lower
than that observed with native IgG IC, thereby demonstrating that
targeting the immunostimulatory potential of FcRn using com-
plexes formed with IgG variants having increased FcRn binding
(15) and which are restricted to a single defined tumor antigen
is a tractable and effective anti-tumor therapeutic approach (37).
Further, proof-of-principle experiments demonstrated that ex vivo
priming of CD8+ T-cells towards a single FcRn-targeted antigen
expressed by tumor cells enables subsequent in vivo protection
from the seeding of lung metastases. These studies demonstrate
the potential of therapeutically promoting tumor immune surveil-
lance in healthy, high-risk individuals by enhancing the baseline
cytotoxic potential of the intestine by targeting and modulating
FcRn binding to IgG (37).
FcRn DEPENDENT NON-INVASIVE MUCOSAL DRUG
DELIVERY AND MUCOSAL VACCINATION STRATEGIES
FcRn is one of the few molecules known to move from the lumi-
nal to serosal membranes of the polarized cells that form the
epithelial barriers of the lung and intestine (16, 43), thereby pro-
viding unique opportunities for potent non-invasive delivery of
protein therapeutics across mucosal interfaces. This non-invasive
mucosal drug delivery approach capitalizes upon two important
prerequisites: (i) the knowledge that FcRn is functionally expressed
throughout adult life in the upper and central airways as well
as intestines of humans and non-human primates (8, 9, 44, 45)
(ii) the knowledge that FcRn binds to the Fc portion of IgG in a
pH-dependent manner and prevents degradation of monomeric
ligand. Thus, when linked to an Fc fragment, therapeutic mole-
cules benefit from both FcRn dependent half-life extension (15)
and also mucosal absorption across epithelial boundaries.
The first study successfully demonstrating FcRn dependent
delivery of an Fc containing therapeutic was performed in mice
with a fusion protein between mouse erythropoietin (Epo) and
the Fc fragment of mouse IgG1, showing that bioactive Fc-Epo
fusion protein was successfully absorbed FcRn dependently via the
respiratory epithelium (8). In subsequent studies in non-human
primates, pulmonary delivery of a human Epo Fc-fusion protein
was also successfully accomplished when the fusion proteins were
aerosolized with a particle size of 4–6 mm to target the upper air-
ways (44). In both mice and monkeys, the FcRn-dependence of
this transepithelial transport was proven by the demonstration
that an EpoFc-fusion containing the non-FcRn binding IHH vari-
ant of IgG was only poorly absorbed (44). In addition to that, it
has already been demonstrated that this pathway is also operative
in humans. A phase I clinical trial assessing the efficacy of the
delivery of an Epo Fc-fusion protein into the bloodstream after
administration of the fusion protein in the upper airways was
able to show a dose-dependent uptake of the fusion protein with
retained biologic activity (46). These studies laid the foundation
for the broader possibility of transepithelial delivery of different
types of Fc-fused macromolecular cargo including interferon-
α, interferon-β, follicle-stimulating hormone, and nanoparticles
(47–50). Thus, these studies demonstrate that FcRn-dependent
drug delivery across mucosal surfaces is a novel non-invasive
delivery approach that is both potent and clinically feasible.
Interestingly, exploitation of this mechanism is not necessar-
ily restricted to the adult organism. Using a murine model of
beta-glucuronidase (GUS) deficiency, in which glycosaminoglycan
storage begins in prenatal life, it was shown that a GUS-Fc-fusion
protein, infused into the mothers, was transported across the pla-
centa into the fetus, leading to reduced lysomal storage disease
only in those mice whose mothers were administered GUS-Fc (51).
While this approach outline that FcRn binding to the Fc region of
IgG might be exploited in severe cases for the administration of
Fc-based treatment strategies starting in utero, these studies clearly
imply that pathogenic antibodies can also cross the maternal–
fetal barrier. That this is indeed the case has been shown in a
murine model of fetal and neonatal immune thrombocytopenia
(FNIT) in which FcRn-mediated transplacental transfer of mater-
nal pathogenic antibodies results in the destruction of platelets
in the neonate (52) but saturation of FcRn by intravenous infu-
sion of IgG (IVIG) or blocking of FcRn in the mother prevented
antibody-mediated FNIT (53). Apart from pathogenic antibod-
ies, virion-IgG complexes, as demonstrated for cytomegalovirus,
can disseminate in the placenta and gain access to the fetal circula-
tion by co-opting the FcRn-mediated transplacental IgG transport
pathway (54). Collectively, these studies demonstrate that the rel-
evance of FcRn’s functions in the placenta extend far beyond the
simple acquisition of passive immunity but also have broad impli-
cations for understanding neonatal (patho)immunology and the
development of novel treatment strategies.
As shown recently, the interaction between FcRn and IgG can
not only be co-opted for novel and non-invasive drug delivery
approaches but also for the induction of humoral immunity along
mucosal barriers. FcRn’s ability to confer humoral immunity is
based on its capacity to bidirectionally transcytose IgG molecules
across the epithelium lining mucosal barriers and preliminary
studies have successfully demonstrated that FcRn conferred pro-
tective passive humoral immunity against infections at the site of
pathogen entry when neutralizing antibodies were administered
to the systemic circulation before infection (24, 29, 35). This was
shown in vivo for both bacterial and viral agents, where FcRn-
mediated translocation of systemically administered pathogen-
specific IgG to the mucosal site of pathogen entry within the gas-
trointestinal or genital tract was identified as the key mechanism
responsible for protection (24, 29, 35).
In addition to passive immunity, it has already been demon-
strated in vivo that FcRn can also confer active humoral immunity.
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Table 1 |Therapeutic applications and opportunities derived from FcRn-based biology.
FcRn-based therapeutic approaches Mode of action Therapeutic use Reference
TRANSPORTING IgG
Respiratory epithelium Transcytosis of IgG across
respiratory epithelium
Non-invasive pulmonary delivery of IgG-based
therapeutics in non-human primates and humans
(8, 44, 46–48)
Vaccination against respiratory pathogens
Intestinal epithelium Transcytosis of IgG across
intestinal epithelium
Providing passive and active immunity against enteric
pathogens and infections
(31, 34, 35, 58)
Transepithelial transport of
Fc-targeted nanoparticles
Enabling drugs currently limited by low bioavailability
to be efficiently delivered through oral administration
Genitourinary epithelium Transcytosis of IgG across
genitourinary epithelium
Providing passive and active immunity against
infections with genitourinary entrance
(55, 56)
Placenta Transcytosis of IgG across the
placenta from mother to fetus
Providing passive immunity to fetus (51–53, 59–61)
Transplacental delivery of IgG-based therapeutics
REGULATING IgG HALF-LIFE
Extending serum half-life of IgG and
IgG-based therapeutics by augmenting
FcRn interactions
Increasing FcRn binding with
selective mutations within the IgG
Fc fragment that enable
pH-dependent binding of IgG
Increasing bioavailability of IgG- and IgG-based
therapeutics in serum and tissue, effectiveness
shown for
(42, 62–66)
Prolonging factor VIII and IX serum half-life for
hemophilia treatment
Enhanced anti-tumor activity
Protection against (S)HIV
Increasing FcRn binding to
multimeric IgG containing immune
complexes
Increasing and inducing MHC I and MHC II antigen
presentation
(21, 31, 34, 36,
37, 67)
Increasing and inducing antigen-specific T-cell
responses
Relevance and effectiveness shown for
Tumor protection at mucosal sites (intestines, lung)
Vaccination with tumor antigen for increased
anti-tumor surveillance
Reducing serum half-life of IgG- and
IgG-based therapeutics
IVIG effect and saturating FcRn
binding
Amelioration of IgG-mediated diseases such as
Immune thrombocytopenic purpura
Myasthenia gravis
(15, 19, 68–78)
Peptide mimetics or anti-FcRn
antibodies that block IgG binding
Engineered antibodies with higher
FcRn affinity that enhance IgG
degradation (Abdegs)
Colitis
Arthritis
Pemphigus vulgaris
Autoimmune encephalomyelitis
Lupus nephritis
A prerequisite in these studies was that pathogens were, in order to
enable FcRn-mediated transport of the antigen across the mucosal
barrier, presented as Fc-fusion proteins and were administered in
the presence of potent adjuvants to force an immune response.
Intranasal immunization with a fusion protein between herpes
simplex virus type-2 (HSV-2) glycoprotein gD and the Fc domain
of IgG2a together with the adjuvant CpG, protected wild type,
but not FcRn knockout, mice after intravaginal challenge with
virulent HSV-2 and this immunization strategy induced an effi-
cient mucosal and systemic antibody response as well B- and
T-cell immunity (55). Similarly, mice that were intranasally vacci-
nated with a fusion protein between HIV Gag p24 and the Fc of
mouse IgG2a together with CpG as an adjuvant developed local
and systemic immunity, including durable B- and T-cell mem-
ory. In these experiments, Gag-specific immunity was sufficiently
potent to protect against an intravaginal challenge with recom-
binant vaccine virus expressing the HIV Gag protein (56). Of
particular importance, mice lacking FcRn or those immunized
with free antigen or an antigen fused to an Fc fragment disabled in
FcRn binding were not protected against HSV or HIV infection,
thereby highlighting the central role of FcRn and its intact binding
to IgG for efficient mucosal transport across an epithelial bar-
rier and the elicitation of active mucosal immunization (55, 56).
Finally, as shown in transgenic animals, overexpression of FcRn
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can significantly enhance humoral immunity by the following
mechanisms: (i) prolonged IgG half-life, (ii) facilitation of anti-
gen presentation by antigen-presenting cells (APCs), resulting in
increased antigen-specific humoral immune response with larger
numbers of antigen-specific B cells, and (iii) generation of anti-
bodies against weakly immunogenic antigens, as recently reviewed
elsewhere (57). Table 1 summarizes therapeutic applications and
opportunities derived from FcRn-based biology.
CONCLUDING REMARKS
In the recent past, the view of FcRn has changed from a recep-
tor, which contributes to passive immunity via transcytosis of IgG
molecules to that of an active signaling and trafficking receptor
that is deeply involved in antigen presentation pathways. It is now
clear that FcRn inherits a fundamental role in classical MHC II pre-
sentation of exogenous antigen as well in the cross-presentation
of exogenous antigen on MHC I molecules. The pleiotropic func-
tions enable FcRn to elicit antigen-specific CD4+ and CD8+ T-cell
responses and thus exert broad functions in immune surveillance
and immune homeostasis. Critically, these pathways have already
been shown to have important pathophysiological relevance for
infectious diseases and cancer development along mucosal barri-
ers. Exploitation of the receptor–ligand interaction between FcRn
and IgG has already been successfully used for the development
of novel mucosal vaccination strategies as well as the non-invasive
delivery of Fc-fusion proteins. Thus, the roles that FcRn plays in
guiding the transport of IgG across epithelial barriers and regulat-
ing the recycling of monomeric IgG away from a degradative fate
in lysosomes and preserving IgG half-life or alternatively directing
IgG containing ICs to the antigen presentation machinery present
enormous therapeutic opportunities for translation (Table 1). Our
increasing understanding of the biology of FcRn will likely only
increase the range of therapeutic applications for FcRn-targeted
drugs, which promise to deliver effective treatment for neoplastic,
infectious, and autoimmune diseases.
REFERENCES
1. Huber AH, Kelley RF, Gastinel LN, Bjorkman PJ. Crystallization and stoichiom-
etry of binding of a complex between a rat intestinal Fc receptor and Fc. J Mol
Biol (1993) 230:1077–83. doi:10.1006/jmbi.1993.1220
2. Sanchez LM, Penny DM, Bjorkman PJ. Stoichiometry of the interaction between
the major histocompatibility complex-related Fc receptor and its Fc ligand. Bio-
chemistry (1999) 38:9471–6. doi:10.1021/bi9907330
3. Schuck P, Radu CG, Ward ES. Sedimentation equilibrium analysis of recom-
binant mouse FcRn with murine IgG1. Mol Immunol (1999) 36:1117–25.
doi:10.1016/S0161-5890(99)00093-0
4. Raghavan M, Bonagura VR, Morrison SL, Bjorkman PJ. Analysis of the pH
dependence of the neonatal Fc receptor/immunoglobulin G interaction using
antibody and receptor variants. Biochemistry (1995) 34:14649–57. doi:10.1021/
bi00045a005
5. Raghavan M, Chen MY, Gastinel LN, Bjorkman PJ. Investigation of the inter-
action between the class I MHC-related Fc receptor and its immunoglobulin G
ligand. Immunity (1994) 1:303–15. doi:10.1016/1074-7613(94)90082-5
6. Medesan C, Cianga P, Mummert M, Stanescu D, Ghetie V,Ward ES. Comparative
studies of rat IgG to further delineate the Fc:FcRn interaction site. Eur J Immunol
(1998) 28:2092–100. doi:10.1002/(SICI)1521-4141(199807)28:07<2092::AID-
IMMU2092>3.0.CO;2-E
7. Medesan C, Matesoi D, Radu C, Ghetie V, Ward ES. Delineation of the amino
acid residues involved in transcytosis and catabolism of mouse IgG1. J Immunol
(1997) 158:2211–7.
8. Spiekermann GM, Finn PW, Ward ES, Dumont J, Dickinson BL, Blumberg RS,
et al. Receptor-mediated immunoglobulin G transport across mucosal barriers
in adult life: functional expression of FcRn in the mammalian lung. J Exp Med
(2002) 196:303–10. doi:10.1084/jem.20020400
9. Dickinson BL, Badizadegan K, Wu Z, Ahouse JC, Zhu X, Simister NE, et al.
Bidirectional FcRn-dependent IgG transport in a polarized human intestinal
epithelial cell line. J Clin Invest (1999) 104:903–11. doi:10.1172/JCI6968
10. Ober RJ, Martinez C, Vaccaro C, Zhou J, Ward ES. Visualizing the site and
dynamics of IgG salvage by the MHC class I-related receptor, FcRn. J Immunol
(2004) 172:2021–9. doi:10.4049/jimmunol.172.4.2021
11. Ward ES, Martinez C, Vaccaro C, Zhou J, Tang Q, Ober RJ. From sort-
ing endosomes to exocytosis: association of Rab4 and Rab11 GTPases with
the Fc receptor, FcRn, during recycling. Mol Biol Cell (2005) 16:2028–38.
doi:10.1091/mbc.E04-08-0735
12. Ward ES, Zhou J, Ghetie V, Ober RJ. Evidence to support the cellular mechanism
involved in serum IgG homeostasis in humans. Int Immunol (2003) 15:187–95.
doi:10.1093/intimm/dxg018
13. Andersen JT, Sandlie I. The versatile MHC class I-related FcRn protects
IgG and albumin from degradation: implications for development of new
diagnostics and therapeutics. Drug Metab Pharmacokinet (2009) 24:318–32.
doi:10.2133/dmpk.24.318
14. Baker K, Rath T, Pyzik M, Blumberg RS. The role of FcRn in antigen presenta-
tion. Front Immunol (2014) 5:408. doi:10.3389/fimmu.2014.00408
15. Rath T, Baker K, Dumont JA, Peters RT, Jiang H, Qiao SW, et al. Fc-fusion pro-
teins and FcRn: structural insights for longer-lasting and more effective thera-
peutics. Crit Rev Biotechnol (2013). doi:10.3109/07388551.2013.834293
16. Rath T, Kuo TT, Baker K, Qiao SW, Kobayashi K, Yoshida M, et al. The immuno-
logic functions of the neonatal Fc receptor for IgG. J Clin Immunol (2013)
33(Suppl 1):S9–17. doi:10.1007/s10875-012-9768-y
17. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev
Immunol (2007) 7:715–25. doi:10.1038/nri2155
18. Akilesh S, Christianson GJ, Roopenian DC, Shaw AS. Neonatal FcR expression
in bone marrow-derived cells functions to protect serum IgG from catabolism.
J Immunol (2007) 179:4580–8. doi:10.4049/jimmunol.179.7.4580
19. Kobayashi K, Qiao SW, Yoshida M, Baker K, Lencer WI, Blumberg RS. An FcRn-
dependent role for anti-flagellin immunoglobulin G in pathogenesis of colitis
in mice. Gastroenterology (2009) 137(1746–1756):e1741. doi:10.1053/j.gastro.
2009.07.059
20. Montoyo HP, Vaccaro C, Hafner M, Ober RJ, Mueller W, Ward ES. Condi-
tional deletion of the MHC class I-related receptor FcRn reveals the sites
of IgG homeostasis in mice. Proc Natl Acad Sci USA (2009) 106:2788–93.
doi:10.1073/pnas.0810796106
21. Qiao SW, Kobayashi K, Johansen FE, Sollid LM, Andersen JT, Milford E, et al.
Dependence of antibody-mediated presentation of antigen on FcRn. Proc Natl
Acad Sci U S A (2008) 105:9337–42. doi:10.1073/pnas.0801717105
22. Akilesh S, Huber TB, Wu H, Wang G, Hartleben B, Kopp JB, et al. Podocytes use
FcRn to clear IgG from the glomerular basement membrane. Proc Natl Acad Sci
U S A (2008) 105:967–72. doi:10.1073/pnas.0711515105
23. Antohe F, Radulescu L, Gafencu A, Ghetie V, Simionescu M. Expression
of functionally active FcRn and the differentiated bidirectional transport of
IgG in human placental endothelial cells. Hum Immunol (2001) 62:93–105.
doi:10.1016/S0198-8859(00)00244-5
24. Bai Y,Ye L, Tesar DB, Song H, Zhao D, Björkman PJ, et al. Intracellular neutraliza-
tion of viral infection in polarized epithelial cells by neonatal Fc receptor (FcRn)-
mediated IgG transport. Proc Natl Acad Sci U S A (2011) 108(45):18406–11.
doi:10.1073/pnas.1115348108
25. Claypool SM, Dickinson BL, Wagner JS, Johansen FE, Venu N, Borawski
JA, et al. Bidirectional transepithelial IgG transport by a strongly polarized
basolateral membrane Fcgamma-receptor. Mol Biol Cell (2004) 15:1746–59.
doi:10.1091/mbc.E03-11-0832
26. Claypool SM, Dickinson BL, Yoshida M, Lencer WI, Blumberg RS. Functional
reconstitution of human FcRn in Madin-Darby canine kidney cells requires
co-expressed human beta 2-microglobulin. J Biol Chem (2002) 277:28038–50.
doi:10.1074/jbc.M202367200
27. Ellinger I, Rothe A, Grill M, Fuchs R. Apical to basolateral transcytosis and apical
recycling of immunoglobulin G in trophoblast-derived BeWo cells: effects of low
temperature, nocodazole, and cytochalasin D. Exp Cell Res (2001) 269:322–31.
doi:10.1006/excr.2001.5330
28. Ellinger I, Schwab M, Stefanescu A, Hunziker W, Fuchs R. IgG transport
across trophoblast-derived BeWo cells: a model system to study IgG trans-
port in the placenta. Eur J Immunol (1999) 29:733–44. doi:10.1002/(SICI)1521-
4141(199903)29:03<733::AID-IMMU733>3.0.CO;2-C
Frontiers in Immunology | Immunotherapies and Vaccines January 2015 | Volume 5 | Article 664 | 6
Rath et al. FcRn in mucosal immunity
29. Li Z, Palaniyandi S, Zeng R, Tuo W, Roopenian DC, Zhu X. Transfer of IgG in
the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) con-
fers protective immunity to vaginal infection. Proc Natl Acad Sci U S A (2011)
108:4388–93. doi:10.1073/pnas.1012861108
30. Roopenian DC, Christianson GJ, Sproule TJ, Brown AC, Akilesh S, Jung N,
et al. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG
homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol (2003) 170:3528–33.
doi:10.4049/jimmunol.170.7.3528
31. Yoshida M, Claypool SM, Wagner JS, Mizoguchi E, Mizoguchi A, Roopenian
DC, et al. Human neonatal Fc receptor mediates transport of IgG into luminal
secretions for delivery of antigens to mucosal dendritic cells. Immunity (2004)
20:769–83. doi:10.1016/j.immuni.2004.05.007
32. Belzer C, Liu Q, Carroll MC, Bry L. The role of specific IgG and complement in
combating a primary mucosal infection of the gut epithelium. Eur J Microbiol
Immunol (Bp) (2011) 1:311–8. doi:10.1556/EuJMI.1.2011.4.7
33. Bry L, Brenner MB. Critical role of T cell-dependent serum antibody, but not
the gut-associated lymphoid tissue, for surviving acute mucosal infection with
Citrobacter rodentium, an attaching and effacing pathogen. J Immunol (2004)
172:433–41. doi:10.4049/jimmunol.172.1.433
34. Yoshida M, Kobayashi K, Kuo TT, Bry L, Glickman JN, Claypool SM, et al.
Neonatal Fc receptor for IgG regulates mucosal immune responses to luminal
bacteria. J Clin Invest (2006) 116:2142–51. doi:10.1172/JCI27821
35. Ben Suleiman Y, Yoshida M, Nishiumi S, Tanaka H, Mimura T, Nobutani K,
et al. Neonatal Fc receptor for IgG (FcRn) expressed in the gastric epithe-
lium regulates bacterial infection in mice. Mucosal Immunol (2012) 5:87–98.
doi:10.1038/mi.2011.53
36. Baker K, Qiao SW, Kuo TT, Aveson VG, Platzer B, Andersen JT, et al. Neonatal Fc
receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes
by CD8-CD11b+ dendritic cells. Proc Natl Acad Sci U S A (2011) 108:9927–32.
doi:10.1073/pnas.1019037108
37. Baker K, Rath T, Flak MB, Arthur JC, Chen Z, Glickman JN, et al. Neonatal
Fc receptor expression in dendritic cells mediates protective immunity against
colorectal cancer. Immunity (2013) 39:1095–107. doi:10.1016/j.immuni.2013.
11.003
38. Zhu X, Meng G, Dickinson BL, Li X, Mizoguchi E, Miao L, et al. MHC class
I-related neonatal Fc receptor for IgG is functionally expressed in monocytes,
intestinal macrophages, and dendritic cells. J Immunol (2001) 166:3266–76.
doi:10.4049/jimmunol.166.5.3266
39. Qiao SW, Bergseng E, Molberg O, Jung G, Fleckenstein B, Sollid LM. Refining the
rules of gliadin T cell epitope binding to the disease-associated DQ2 molecule
in celiac disease: importance of proline spacing and glutamine deamidation. J
Immunol (2005) 175:254–61. doi:10.4049/jimmunol.175.1.254
40. Amigorena S, Savina A. Intracellular mechanisms of antigen cross presentation
in dendritic cells. Curr Opin Immunol (2010) 22:109–17. doi:10.1016/j.coi.2010.
01.022
41. Tao MH, Morrison SL. Studies of aglycosylated chimeric mouse-human IgG.
Role of carbohydrate in the structure and effector functions mediated by the
human IgG constant region. J Immunol (1989) 143:2595–601.
42. Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, et al.
Enhanced antibody half-life improves in vivo activity. Nat Biotechnol (2010)
28:157–9. doi:10.1038/nbt.1601
43. Baker K, Qiao SW, Kuo T, Kobayashi K, Yoshida M, Lencer WI, et al. Immune
and non-immune functions of the (not so) neonatal Fc receptor, FcRn. Semin
Immunopathol (2009) 31:223–36. doi:10.1007/s00281-009-0160-9
44. Bitonti AJ, Dumont JA, Low SC, Peters RT, Kropp KE, Palombella VJ, et al. Pul-
monary delivery of an erythropoietin Fc fusion protein in non-human primates
through an immunoglobulin transport pathway. Proc Natl Acad Sci U S A (2004)
101:9763–8. doi:10.1073/pnas.0403235101
45. Israel EJ, Taylor S, Wu Z, Mizoguchi E, Blumberg RS, Bhan A, et al. Expression of
the neonatal Fc receptor, FcRn, on human intestinal epithelial cells. Immunology
(1997) 92:69–74. doi:10.1046/j.1365-2567.1997.00326.x
46. Dumont JA, Bitonti AJ, Clark D, Evans S, Pickford M, Newman SP. Deliv-
ery of an erythropoietin-Fc fusion protein by inhalation in humans through
an immunoglobulin transport pathway. J Aerosol Med (2005) 18:294–303.
doi:10.1089/jam.2005.18.294
47. Bitonti AJ, Dumont JA. Pulmonary administration of therapeutic proteins using
an immunoglobulin transport pathway. Adv Drug Deliv Rev (2006) 58:1106–18.
doi:10.1016/j.addr.2006.07.015
48. Low SC, Nunes SL, Bitonti AJ, Dumont JA. Oral and pulmonary delivery of
FSH-Fc fusion proteins via neonatal Fc receptor-mediated transcytosis. Hum
Reprod (2005) 20:1805–13. doi:10.1093/humrep/deh896
49. Vallee S, Rakhe S, Reidy T, Walker S, Lu Q, Sakorafas P, et al. Pulmonary adminis-
tration of interferon Beta-1a-fc fusion protein in non-human primates using an
immunoglobulin transport pathway. J Interferon Cytokine Res (2012) 32:178–84.
doi:10.1089/jir.2011.0048
50. Pridgen EM,Alexis F, Kuo TT, Levy-Nissenbaum E, Karnik R, Blumberg RS, et al.
Transepithelial transport of Fc-targeted nanoparticles by the neonatal fc receptor
for oral delivery. Sci Transl Med (2013) 5:213ra167. doi:10.1126/scitranslmed.
3007049
51. Grubb JH,Vogler C, TanY, Shah GN, MacRae AF, Sly WS. Infused Fc-tagged beta-
glucuronidase crosses the placenta and produces clearance of storage in utero in
mucopolysaccharidosis VII mice. Proc Natl Acad Sci U S A (2008) 105:8375–80.
doi:10.1073/pnas.0803715105
52. Chen P, Li C, Lang S, Zhu G, Reheman A, Spring CM, et al. Animal model
of fetal and neonatal immune thrombocytopenia: role of neonatal Fc receptor
in the pathogenesis and therapy. Blood (2010) 116(18):3660–8. doi:10.1182/
blood-2010-05-284919
53. Li C, Piran S, Chen P, Lang S, Zarpellon A, Jin JW, et al. The maternal immune
response to fetal platelet GPIbalpha causes frequent miscarriage in mice that can
be prevented by intravenous IgG and anti-FcRn therapies. J Clin Invest (2011)
121:4537–47. doi:10.1172/JCI57850
54. Maidji E, McDonagh S, Genbacev O, Tabata T, Pereira L. Maternal antibodies
enhance or prevent cytomegalovirus infection in the placenta by neonatal Fc
receptor-mediated transcytosis. Am J Pathol (2006) 168:1210–26. doi:10.2353/
ajpath.2006.050482
55. Ye L, Zeng R, Bai Y, Roopenian DC, Zhu X. Efficient mucosal vaccina-
tion mediated by the neonatal Fc receptor. Nat Biotechnol (2011) 29:158–63.
doi:10.1038/nbt.1742
56. Lu L, Palaniyandi S, Zeng R, Bai Y, Liu X, Wang Y, et al. A neonatal Fc receptor-
targeted mucosal vaccine strategy effectively induces HIV-1 antigen-specific
immunity to genital infection. J Virol (2011) 85:10542–53. doi:10.1128/JVI.
05441-11
57. Kacskovics I, Cervenak J, Erdei A, Goldsby RA, Butler JE. Recent advances using
FcRn overexpression in transgenic animals to overcome impediments of stan-
dard antibody technologies to improve the generation of specific antibodies.
MAbs (2011) 3:431–9. doi:10.4161/mabs.3.5.17023
58. Cong Y, Feng T, Fujihashi K, Schoeb TR, Elson CO. A dominant, coordinated T
regulatory cell-IgA response to the intestinal microbiota. Proc Natl Acad Sci U S
A (2009) 106:19256–61. doi:10.1073/pnas.0812681106
59. Leach JL, Sedmak DD, Osborne JM, Rahill B, Lairmore MD, Anderson CL. Iso-
lation from human placenta of the IgG transporter, FcRn, and localization to
the syncytiotrophoblast: implications for maternal-fetal antibody transport. J
Immunol (1996) 157:3317–22.
60. Simister NE, Story CM. Human placental Fc receptors and the transmis-
sion of antibodies from mother to fetus. J Reprod Immunol (1997) 37:1–23.
doi:10.1016/S0165-0378(97)00068-5
61. Simister NE, Story CM, Chen HL, Hunt JS. An IgG-transporting Fc receptor
expressed in the syncytiotrophoblast of human placenta. Eur J Immunol (1996)
26:1527–31. doi:10.1002/eji.1830260718
62. Dumont JA, Liu T, Low SC, Zhang X, Kamphaus G, Sakorafas P, et al.
Prolonged activity of a recombinant factor VIII-Fc fusion protein in
hemophilia A mice and dogs. Blood (2012) 119:3024–30. doi:10.1182/blood-
2011-08-367813
63. Mahlangu J, Powell JS, Ragni MV, Chowdary P, Josephson NC, Pabinger I, et al.
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia
A. Blood (2014) 123:317–25. doi:10.1182/blood-2013-10-529974
64. Powell JS, Pasi KJ, Ragni MV, Ozelo MC,Valentino LA, Mahlangu JN, et al. Phase
3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J
Med (2013) 369:2313–23. doi:10.1056/NEJMoa1305074
65. Powell JS, Josephson NC, Quon D, Ragni MV, Cheng G, Li E, et al. Safety and
prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia
A patients. Blood (2012) 119:3031–7. doi:10.1182/blood-2011-09-382846
66. Shapiro AD, Ragni MV, Valentino LA, Key NS, Josephson NC, Powell JS, et al.
Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and pro-
longed activity in a phase 1/2a study in hemophilia B patients. Blood (2012)
119:666–72. doi:10.1182/blood-2011-07-367003
www.frontiersin.org January 2015 | Volume 5 | Article 664 | 7
Rath et al. FcRn in mucosal immunity
67. Baker K, Rath T, Lencer WI, Fiebiger E, Blumberg RS. Cross-presentation of
IgG-containing immune complexes. Cell Mol Life Sci (2013) 70(8):1319–34.
doi:10.1007/s00018-012-1100-8
68. Akilesh S, Petkova S, Sproule TJ, Shaffer DJ, Christianson GJ, Roopenian D.
The MHC class I-like Fc receptor promotes humorally mediated autoimmune
disease. J Clin Invest (2004) 113:1328–33. doi:10.1172/JCI18838
69. Hansen RJ, Balthasar JP. Intravenous immunoglobulin mediates an increase in
anti-platelet antibody clearance via the FcRn receptor. Thromb Haemost (2002)
88:898–9.
70. Li N, Zhao M, Hilario-Vargas J, Prisayanh P, Warren S, Diaz LA, et al. Complete
FcRn dependence for intravenous Ig therapy in autoimmune skin blistering
diseases. J Clin Invest (2005) 115:3440–50. doi:10.1172/JCI24394
71. Liu L, Garcia AM, Santoro H, Zhang Y, McDonnell K, Dumont J, et al.
Amelioration of experimental autoimmune myasthenia gravis in rats by neona-
tal FcR blockade. J Immunol (2007) 178:5390–8. doi:10.4049/jimmunol.178.8.
5390
72. Liu Z, Roopenian DC, Zhou X, Christianson GJ, Diaz LA, Sedmak DD, et al.
Beta2-microglobulin-deficient mice are resistant to bullous pemphigoid. J Exp
Med (1997) 186:777–83. doi:10.1084/jem.186.5.777
73. Nimmerjahn F, Ravetch JV. The antiinflammatory activity of IgG: the intra-
venous IgG paradox. J Exp Med (2007) 204:11–5. doi:10.1084/jem.20061788
74. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous
immunoglobulin. Annu Rev Immunol (2008) 26:513–33. doi:10.1146/annurev.
immunol.26.021607.090232
75. Patel DA, Puig-Canto A, Challa DK, Perez Montoyo H, Ober RJ,Ward ES. Neona-
tal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine
model. J Immunol (2011) 187:1015–22. doi:10.4049/jimmunol.1003780
76. Petkova SB, Akilesh S, Sproule TJ, Christianson GJ, Al Khabbaz H, Brown AC,
et al. Enhanced half-life of genetically engineered human IgG1 antibodies in a
humanized FcRn mouse model: potential application in humorally mediated
autoimmune disease. Int Immunol (2006) 18:1759–69. doi:10.1093/intimm/
dxl110
77. Mezo AR, McDonnell KA, Hehir CA, Low SC, Palombella VJ, Stattel JM,
et al. Reduction of IgG in nonhuman primates by a peptide antagonist of the
neonatal Fc receptor FcRn. Proc Natl Acad Sci U S A (2008) 105:2337–42.
doi:10.1073/pnas.0708960105
78. Mezo AR, Sridhar V, Badger J, Sakorafas P, Nienaber V. X-ray crystal structures of
monomeric and dimeric peptide inhibitors in complex with the human neona-
tal Fc receptor, FcRn. J Biol Chem (2010) 285:27694–701. doi:10.1074/jbc.M110.
120667
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 22 August 2014; accepted: 10 December 2014; published online: 05 January
2015.
Citation: Rath T, Baker K, Pyzik M and Blumberg RS (2015) Regulation of immune
responses by the neonatal Fc receptor and its therapeutic implications. Front. Immunol.
5:664. doi: 10.3389/fimmu.2014.00664
This article was submitted to Immunotherapies and Vaccines, a section of the journal
Frontiers in Immunology.
Copyright © 2015 Rath, Baker, Pyzik and Blumberg . This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal is cited,
in accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
Frontiers in Immunology | Immunotherapies and Vaccines January 2015 | Volume 5 | Article 664 | 8
